Figure 1

Figure 2

Figure 3

Figure 4

Diagnostic performance of parameters for differentiation between isocitrate dehydrogenase 1 (IDH1) mutant and wild-type gliomas
| Parameter | AUC (95% CI) | Sensitivity (%) | Specificity (%) | Cutoff value |
|---|---|---|---|---|
| Ktrans (min−1) | 0.773 (0.563–0.983) | 77.8 | 75.0 | > 0.062 |
| ve | 0.760 (0.569–0.951) | 94.4 | 58.3 | > 0.119 |
| vp | 0.680 (0.451–0.909) | 55.6 | 91.7 | > 0.029 |
| ADC0,1000 (×10−3 mm2/s) | 0.718 (0.531–0.904) | 83.3 | 75.0 | ≤ 1.002 |
| SPF (%) | 0.861 (0.686–0.959) | 94.4 | 75.0 | > 14.500 |
| D (×10−3 mm2/s) | 0.727 (0.541–0.913) | 72.2 | 83.3 | > 1.065 |
| D* (×10−3 mm2/s) | 0.690 (0.493–0.886) | 44.4 | 91.4 | ≤ 5.959 |
| f (%) | 0.810 (0.658–0.963) | 72.2 | 83.3 | > 3.617 |
Parameters derived from dynamic contrast-enhanced (DCE) MRI and diffusion-weighted imaging (DWI) between WHO grade II and III gliomas
| Parameter | Grade II | Grade III | P-value |
|---|---|---|---|
| Ktrans (min−1) | 0.067 ± 0.048 | 0.116 ± 0.064 | 0.013 |
| ve | 0.071 ± 0.057 | 0.401 ± 0.344 | 0.018 |
| vp | 0.036 ± 0.020 | 0.051 ± 0.018 | 0.035 |
| ADC0,1000 (×10−3 mm2/s) | 1.093 ± 0.203 | 0.904 ± 0.184 | 0.028 |
| SPF (%) | 10.78 ± 4.378 | 16.391 ± 5.471 | 0.012 |
| D (×10−3 mm2/s) | 1.194 ± 0.261 | 0.949 ± 0.169 | 0.021 |
| D* (×10−3 mm2/s) | 6.692 ± 1.564 | 8.618 ± 2.215 | 0.037 |
| f (%) | 3.315 ± 1.536 | 6.380 ± 3.419 | 0.020 |
Parameters derived from dynamic contrast-enhanced (DCE) MRI and diffusion-weighted imaging (DWI) between isocitrate dehydrogenase 1 (IDH1) mutant and wild-type gliomas
| Parameter | IDH1 mutant | IDH1 wild-type | P-value* |
|---|---|---|---|
| Ktrans (min−1) | 0.054 ± 0.024 | 0.123 ± 0.073 | 0.007 |
| ve | 0.052 ± 0.035 | 0.121 ± 0.080 | 0.007 |
| vp | 0.032 ± 0.015 | 0.051 ± 0.022 | 0.015 |
| ADC0,1000 (×10−3 mm2/s) | 1.123 ± 0.185 | 0.923 ± 0.199 | 0.009 |
| SPF (%) | 9.572 ± 3.437 | 16.332 ± 4.925 | < 0.001 |
| D (×10−3 mm2/s) | 1.108 ± 0.245 | 0.959 ± 0.146 | 0.047 |
| D* (×10−3 mm2/s) | 6.546 ± 1.757 | 8.196 ± 1.794 | 0.020 |
| f (%) | 3.080 ± 1.581 | 5.712 ± 2.924 | 0.005 |
Patient characteristics
| Characteristic | IDH1 mutants (n = 18) | IDH1 wild-type (n = 12) |
|---|---|---|
| Mean age (y)a | 42.8 (22–67) | 47.9 (19–78) |
| Sex distribution (M/F)b | 10/8 | 7/5 |
| WHO grade | ||
| II | 15 | 7 |
| III | 3 | 5 |
| Histologic type | ||
| Astrocytoma | 12 | 5 |
| Oligodendroglioma | 3 | 0 |
| Oligoastrocytoma | 0 | 1 |
| Anaplastic astrocytoma | 1 | 3 |
| Anaplastic oligodendroglioma | 1 | 2 |
| Anaplastic oligoastrocytoma | 1 | 1 |